Top

Tag: biotech


Biotech, Industry

Biotechnology Gets $2 Billion Boost from the White House

September 15, 2022

Via: GEN

This week has been one of the most exciting that the biotechnology community has seen for some time. Plans that have been in the making for a decade are finally being brought to fruition by actions taken by the Biden […]


Mergers and Acquisitions

Aptar Pharma Acquires Metaphase Design Group

September 6, 2022

Via: Contract Pharma

Aptar Pharma, a leader in drug delivery and active material science solutions and services, has acquired Metaphase Design Group Inc., a leader in applying the science of human factors engineering and ergonomics to product design. The acquisition expands Aptar Pharma’s […]


Mergers and Acquisitions

Novo Nordisk steps up sickle cell push with $1.1bn Forma buy

September 2, 2022

Via: Pharmaphorum

The $20-per-share agreement was a premium of 92% over Forma’s closing share price yesterday, but its stock leaped after the deal was announced from $13.40 to just under the deal price. The biotech went public via a $278 million IPO […]


Manufacturing, Research and Development

Streamlining Bulk mAb Manufacturing

September 2, 2022

Via: Biopharm International

With biosimilars entering the market, and more expected to reach the market in the near future, the need for good manufacturing practice (GMP) compliance is growing more crucial for bulk monoclonal antibody (mAb) manufacturing. Beyond innovator biologics, biosimilars are expected […]


Cell and Gene Therapy, Industry

Sangamo presses ahead with Fabry disease gene therapy

September 1, 2022

Via: Biopharma Dive

Sangamo Therapeutics is continuing to enroll and treat patients with a rare genetic condition called Fabry disease in an early clinical trial of a gene therapy it is developing, announcing Tuesday updated results from the first 11 study participants. Data […]


News

Ori Biotech Expands Expertise and Personnel, Adds New Facilities

September 1, 2022

Via: Contract Pharma

Ori Biotech Ltd., a leader in cell and gene therapy (CGT) manufacturing technology, has shared details of its strategic expansion plan following its $100 million Series B funding round in January 2022, including adding key expertise and personnel and new […]


Cell and Gene Therapy, Industry

Beam details reasons for FDA hold on base editing cancer therapy

August 31, 2022

Via: Biopharma Dive

FDA officials are proceeding with caution as the gene editing field advances. In another recent example, the agency had issued a partial clinical hold to Editas Medicine before this July allowing that company to proceed with testing of a sickle […]


Mergers and Acquisitions

Biotech startup Ocean pivots from IPO to SPAC merger

August 31, 2022

Via: Biopharma Dive

Ocean Biomedical, a small Rhode Island-based biotechnology company, will go public through a SPAC merger with Aesther Healthcare Acquisition Corp, pivoting from plans to list shares through a traditional initial public offering. Ocean Biomedical focuses on oncology, infectious diseases and […]


Industry, Vaccines

COVID Vaccine Won’t Raise Stroke Risk

August 30, 2022

Via: Drugs.com

COVID-19 vaccines do not increase your risk for stroke, new research shows, but severe COVID infection does, and experts hope the finding will ease the concerns of those who are hesitant to get the shot. “We now know that patients […]


Manufacturing, Research and Development

ADHD Drug Adderall in Short Supply

August 29, 2022

Via: Drugs.com

Labor shortages at Teva Pharmaceuticals have made Adderall, a widely used attention-deficit/hyperactivity disorder (ADHD) drug, hard to find in some drugstores. But the U.S. Food and Drug Administration noted that there’s no overall shortage of ADHD medications. Only Teva is […]


Clinical Trials, Research and Development

Psychedelic clinical trials: What sponsors should know when designing new protocols

August 29, 2022

Via: Biopharma Dive

Psychedelic products are having a renaissance moment. As evidence emerges about their potential for PTSD, depression, cancer-related distress and more, the market for psychedelics could swell from $2 billion in 2020 to $10.75 billion in 2027. With regulators and lawmakers […]


Manufacturing, Mergers and Acquisitions, Research and Development

ElevateBio and the Univ. of Pittsburgh Enter Biomanufacturing Partnership

August 26, 2022

Via: Contract Pharma

ElevateBio and the University of Pittsburgh have entered into a long-term partnership to accelerate the development of cell and gene therapies. Through this agreement, ElevateBio will locate one of its next BaseCamp process development and Good Manufacturing Practice (GMP) manufacturing […]


Cell and Gene Therapy, Industry

Roctavian okay sets up another gene therapy test for Europe

August 26, 2022

Via: Pharmaphorum

The US biotech claimed conditional marketing approval from the European Commission for Roctavian (valoctocogene roxaparvovec) as a treatment for adults with severe haemophilia A, who don’t have a history of developing the antibodies that inhibit the activity of blood-clotting protein […]


Industry, Vaccines

AI-derived cancer vaccines: the pharmaphorum podcast

August 25, 2022

Via: Pharmaphorum

Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science officer respectively of Transgene, to discuss cancer vaccines in general and Transgene’s recent work in the space in particular. […]


Clinical Trials, Research and Development

To build diversity into clinical trials, collaborate at the community level

August 24, 2022

Via: Pharmaphorum

Removing barriers to clinical trial participation for underserved groups is an essential part of addressing health inequalities. Getting there, however, is easier said than done. The Food and Drug Administration’s (FDA) draft guidance, Diversity Plans to Improve Enrollment of Participants […]


Industry, Vaccines

Next-generation RNA technologies: making longer-lasting drugs with a broader reach

August 23, 2022

Via: Biopharma Dive

The key ingredient in the coronavirus vaccines developed by Moderna and BioNTech doesn’t last very long. Once in the body, this messenger RNA, or mRNA, degrades within days. Still, that’s enough time for the vaccines to train the body to […]


Mergers and Acquisitions

Aerie’s glaucoma drug journey ends in $770M sale to Alcon

August 23, 2022

Via: Biopharma Dive

Alcon has agreed to acquire Aerie Pharmaceuticals for about $770 million, betting its sprawling commercial presence can boost the uptake of the biotechnology company’s two glaucoma drugs. Alcon, the former eyecare business of Swiss pharmaceutical giant Novartis, will pay $15.25 […]


Industry, Vaccines

Pfizer, BioNTech seek US okay for Omicron BA.4/BA.5 booster

August 23, 2022

Via: Pharmaphorum

The new version of their Comirnaty vaccine includes mRNA for the spike protein of the wild-type SARS-CoV-2 that first emerged in late 2019, as well as for the BA.4 and BA.5 subvariants of the now-dominant Omicron variant. It will also […]


Clinical Trials, Research and Development

Jazz Pharmaceuticals’ epilepsy drug advances into phase 3 trial

August 22, 2022

Via: Pharma Times

The phase 3 trials will assess Epidiolex over 14 weeks in a randomised, double-blind, placebo-controlled study, enrolling paediatric patients aged one to 18. It is hoped that Epidiolex will ease symptoms associated with Doose syndrome (EMAS), a rarer type of […]


Industry, Vaccines

EU advisors back lower monkeypox jab dose to stretch supplies

August 22, 2022

Via: Pharmaphorum

The recommendation comes after a review of a clinical trial which found that delivering a smaller dose intradermally – just below the top layer of the skin – is as effective as giving the standard dose subcutaneously as recommended on […]